In arthritis and other autoimmune disorders, chronic inflammation is mediated primarily by pro-inflammatory reactive macrophages. Systemic administration of anti-inflammatory agents does not selectively target the affected tissue, or the reactive macrophages and often has significant side effects. HDs have been observed to selectively target reactive macrophages and have been well tolerated in humans. HDTs may provide a superior method for treating localized inflammation, from systemic administration.

In a preclinical study, systemically administered HDs localized to sites of inflammation in arthritic tissues. When alendronate, which binds bone, was conjugated to the HD, the HD was targeted to the bone with less uptake in reactive macrophages away from the bone. These bone targeted HDs (btHDs) demonstrate the ability to tune HDs for targeting specific tissues and treat inflammation and/or bone metabolism. Efficacy studies are planned with btHD therapeutics to evaluate modulators of bone resorption and inflammation.

Presentation Title: Systemic Administration of Novel Hydroxyl Dendrimers to Target Inflammation in Arthritic Tissues

Presentation Date & Time: Saturday, November 7, 2020, 9:00 AM – 11:00 AM EDT

Abstract Number: 0738

Presenters: Jeffrey Cleland, et al.

Session: RA – Animal Models Poster

Session Type: Poster Session B

For more information, abstracts are available online at